Please assess the completion status of the following clinical trial:

Trial Title: Endothelial Facilitation in Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have mild Alzheimer's Disease or Mild Cognitive Impairment (MCI);~* age between 55-85;~* Mini Mental Status Exam (MMSE) between 15-26;~* a caregiver who can provide information, and bring patient to the sessions;~* no known allergies to any of the medications to be used;~* normal renal function; willingness of patient and spouse/responsible caregiver to participate.~Exclusion Criteria:~* Significant Psychiatric disorder;~* stroke; current use of any of the test medications (e.g., statin, L-Arginine, Kuvan);~* phenylketonuria (PKU) ;~* elevated serum phenylalanine level (\>10 mg/dL);~* allergy to any of the medications; current active malignancy;~* renal insufficiency (elevated creatinine above 1.3mg/dl);~* abnormal liver function (Alanine Aminotransferase (ALT) or Aspartate Transaminase (AST) 2x normal);~* other serious disease including coronary insufficiency or congestive heart failure, carotid stenosis greater than 50%, active peptic ulcer, urinary tract or other active infection, cancer (except skin cancer, or 5 years inactive breast or prostate cancer )etc.;~* pregnancy; or~* inability to come to UMass for follow-up. Subjects may continue to take anticholinesterase drugs for Alzheimer's Disease (Aricept, Exelon, Razadyne) and/or Namenda, if they have been on the drug(s) for at least 3 months. Subjects on levodopa and male subjects taking drugs for erectile dysfunction (Viagra, Cialis, Levitra) are cautioned regarding hypotension.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Simvastatin + L-Arginine + Tetrahydrobiopterin (Type: EXPERIMENTAL): Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally

Based on this trial design, predict the completion outcome and termination type (if applicable).